ForwardVue Pharma names Bob Katz as Chief Executive Officer to advance the pre-clinical development of potent long-acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.
| BOSTON, July 27, 2021 /PRNewswire/ -- ForwardVue Pharma names Bob Katz as Chief Executive Officer to advance the pre-clinical development of potent long-acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.
ForwardVue Pharma Appoints CEO Bob Katz is a seasoned life science executive bringing broad, multi-disciplinary expertise in early-stage technology development, clinical applications and successful fundraising. Most recently, Katz was CEO and President of ContraMed where he directed the company from the pre-clinical stage to a successful Phase 3 Clinical Trial and exit. Prior to ContraMed, Katz has held multiple C-level positions at venture-backed startups. “I am excited about the opportunity to advance ForwardVue Pharma’s approach with small molecule technology with the goal of developing a more safe, effective, and durable treatment option for patients with Wet AMD & DME,” said Katz. “I look forward to communicating more about our plans to introduce an option targeted to help a significant unmet need for patients with retinal diseases.” About ForwardVue Pharma Contact: Alan Franklin, MD
SOURCE ForwardVue Pharma |
View original content to download multimedia:
